Table of Contents Hide
May 13 is a busy day for biotechnology company Capricor Therapeutics (NASDAQ: CAPR). The company which focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases recently announced that Capricor CEO Linda Marbán, Ph.D. will present at the American Society of Gene and Cell Therapy’s (ASGCT) 24th annual meeting, being held virtually May 11-14, 2021.
The presentation titled Exosome Delivery of Sars CoV-2 Vaccines will be presented from 11:10 AM – 11:45 AM EDT on May 13th. Interested investors, researchers and analysts can tune in virtually to the meeting platform by visiting: ASGCT.org/2021
Dr. Marbán is excited about the opportunity to present, “We are honored to have been selected as an industry leader on exosome delivery for SARS-CoV-2 vaccinations. This premier international symposium is a key medical conference in our field and brings together the leading scientists and healthcare professionals focused on gene and cell therapies,” the Capricor chief executive officer shared.
American Society of Gene and Cell Therapy is an organization focused on advancing the knowledge, awareness and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease.
The 2021 Annual Meeting is the organization’s 24th in their longstanding history as a catalyst that brings together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease. With more than 4,500 members, ASGCT is the largest professional association dedicated to gene and cell therapies.
Read More: Capricor Therapeutics To Present Final HOPE-2 Trial CAP-1002 Data for Late-Stage Duchenne Muscular Dystrophy (DMD)
Capricor Therapeutics Lead Candidate
Capricor’s core therapeutic technology is CAP-1002. This is an allogeneic cardiac-derived cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and the cytokine storm associated with COVID-19.
Capricor is also developing their exosomes platform technology as a next-generation therapeutic platform. The current focus is on the development of exosomes loaded with nucleic acids, including mRNA, to treat or prevent a variety of diseases.
The technology is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor’s scientific founder, Dr. Eduardo Marbán.
First published in 2007, CDCs have become the subject of more than 100+ peer-reviewed scientific publications and medical journals. CDCs have also been administered to approximately 200 human subjects throughout a variety of clinical trials.
CAP-1002 is made of allogeneic “off-the-shelf” CDCs (cardiosphere-derived cells). These are a type of cardiac cell therapy that has been shown in pre-clinical and clinical studies to exert potent immunomodulatory activity. It is being investigated for its potential to modify the immune system’s activity to encourage cellular regeneration. The cells function by releasing exosomes that are taken up largely by macrophages and T-cells and begin a cycle of repair.
CAP-1002 has been granted orphan drug designation by the FDA for the treatment of DMD.
DMD is Duchenne muscular dystrophy. A genetic disease in which patients lack the protein dystrophin, which is critical for stabilizing muscle cell membranes. Without a functional dystrophin protein, muscle cells are susceptible to damage and progressively die. Patients often experience progressive muscle weakness starting at an early age, loss of ambulation typically in the first decade of life, eventual respiratory and cardiac failure, and an abbreviated lifespan averaging less than three decades.
Capricor Therapeutics Q1 2021 Earnings Update
Capricor Therapeutics is scheduled to present the company’s financial results and recent corporate update for the first quarter ended March 31, 2021, after the market closes on Thursday May 13, 2021. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13.
|Capricor Therapeutics First Quarter 2021 Financial Results and Recent Corporate Update Conference Call and Webcast|
|Date:||Thursday, May 13, 2021|
|Time:||4:30 p.m. ET|
|Conference Call Details:||Toll-Free: 877-451-6152|
|Conference ID: 13719513|